Erwan Beauchamp

Papers

Total Citations

H-Index

About

Dr. Erwan Beauchamp is a leading researcher in chemical biology and cancer therapeutics, with a primary focus on protein lipidation and its role in oncogenic signaling. His most cited work, "Targeting N-myristoylation for therapy of B-cell lymphomas" (2020, 64 citations), represents a landmark contribution to the field. In this study, Beauchamp systematically investigated N-myristoyltransferase (NMT) as a therapeutic target, demonstrating that cancer cells—particularly B-cell lymphomas—exhibit elevated NMT expression and that pharmacological inhibition of N-myristoylation disrupts membrane targeting and critical signaling pathways. This work established a mechanistic foundation for targeting protein myristoylation in hematological malignancies, bridging fundamental lipid biochemistry with translational oncology. Beyond this flagship paper, Beauchamp’s research portfolio encompasses the broader biology of N-terminal modifications and their dysregulation in disease. His contributions have been instrumental in validating NMT as a druggable vulnerability in lymphoma, opening new avenues for targeted therapy. With growing recognition in the chemical biology community, Beauchamp continues to drive innovation at the interface of lipid signaling and cancer drug discovery, making him a pivotal figure in the quest for novel anti-cancer strategies.